Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYAN

Cyanotech (CYAN) Stock Price, News & Analysis

Cyanotech logo

About Cyanotech Stock (NASDAQ:CYAN)

Advanced Chart

Key Stats

Today's Range
$0.32
$0.34
50-Day Range
$2.83
$3.26
52-Week Range
$2.37
$6.29
Volume
10,600 shs
Average Volume
3,483 shs
Market Capitalization
$2.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Receive CYAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyanotech and its competitors with MarketBeat's FREE daily newsletter.

CYAN Stock News Headlines

Q3 2025 Cyanotech Corp Earnings Call
Secure this "AI Fuel" Stock Before the Billionaires Buy It All
The Washington Post says America is running out of a key material needed for AI—and without it, companies like NVIDIA could be forced to shut down. While billionaires like Buffett and Gates scramble to secure access, one under-the-radar firm has quietly locked up supply. Bloomberg even calls it a “monopoly.” And it’s still trading near $20.
See More Headlines

CYAN Stock Analysis - Frequently Asked Questions

Cyanotech Co. (NASDAQ:CYAN) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company earned $5.85 million during the quarter. Cyanotech had a negative net margin of 19.50% and a negative trailing twelve-month return on equity of 44.71%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Allena Pharmaceuticals (ALNA), Clarivate (CCC), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL).

Company Calendar

Last Earnings
11/12/2024
Today
5/18/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAN
Employees
95
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,270,000.00
Pretax Margin
-19.48%

Debt

Sales & Book Value

Annual Sales
$23.07 million
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
0.24

Miscellaneous

Free Float
5,074,000
Market Cap
$2.29 million
Optionable
Not Optionable
Beta
-0.11
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CYAN) was last updated on 5/18/2025 by MarketBeat.com Staff
From Our Partners